Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial
bevacizumab
cerebral metastasis
management
non-small–cell lung cancer
pemetrexed
radiotherapy
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2021
2021
Historique:
received:
28
12
2020
accepted:
11
03
2021
entrez:
5
5
2021
pubmed:
6
5
2021
medline:
6
5
2021
Statut:
epublish
Résumé
The role and timing of whole or stereotaxic brain radiotherapy (BR) in patients with advanced non-small cell lung cancer (aNSCLC) and asymptomatic brain metastases (aBMs) are not well established. This study investigates whether deferring BR until cerebral progression was superior to upfront BR for patients with aNSCLC and aBM. This open-label, multicenter, phase III trial, randomized (1:1) aNSCLC patients with aBMs to receive upfront BR and chemotherapy: platin-pemetrexed and bevacizumab in eligible patients, followed by maintenance pemetrexed with or without bevacizumab, BR arm, or the same chemotherapy with BR only at cerebral progression, chemotherapy (ChT) arm. Primary endpoint was progression-free survival (PFS), secondary endpoints were overall survival (OS), global, extra-cerebral and cerebral objective response rate (ORR), toxicity, and quality of life [ClinicalTrials.gov identifier: NCT02162537]. The trial was stopped early because of slow recruitment. Among 95 included patients, 91 were randomized in 24 centers: 45 to BR and 46 to ChT arms (age: 60 ± 8.1, men: 79%, PS 0/1: 51.7%/48.3%; adenocarcinomas: 92.2%, extra-cerebral metastases: 57.8%, without differences between arms.) Significantly more patients in the BR-arm received BR compare with those in the ChT arm (87% The significant BR rate difference between the two arms suggests that upfront BR is not mandatory in aNSCLC with aBM but this trial failed to show that deferring BR for aBM is superior in terms of PFS from upfront BR.
Sections du résumé
BACKGROUND
BACKGROUND
The role and timing of whole or stereotaxic brain radiotherapy (BR) in patients with advanced non-small cell lung cancer (aNSCLC) and asymptomatic brain metastases (aBMs) are not well established. This study investigates whether deferring BR until cerebral progression was superior to upfront BR for patients with aNSCLC and aBM.
METHODS
METHODS
This open-label, multicenter, phase III trial, randomized (1:1) aNSCLC patients with aBMs to receive upfront BR and chemotherapy: platin-pemetrexed and bevacizumab in eligible patients, followed by maintenance pemetrexed with or without bevacizumab, BR arm, or the same chemotherapy with BR only at cerebral progression, chemotherapy (ChT) arm. Primary endpoint was progression-free survival (PFS), secondary endpoints were overall survival (OS), global, extra-cerebral and cerebral objective response rate (ORR), toxicity, and quality of life [ClinicalTrials.gov identifier: NCT02162537].
RESULTS
RESULTS
The trial was stopped early because of slow recruitment. Among 95 included patients, 91 were randomized in 24 centers: 45 to BR and 46 to ChT arms (age: 60 ± 8.1, men: 79%, PS 0/1: 51.7%/48.3%; adenocarcinomas: 92.2%, extra-cerebral metastases: 57.8%, without differences between arms.) Significantly more patients in the BR-arm received BR compare with those in the ChT arm (87%
CONCLUSION
CONCLUSIONS
The significant BR rate difference between the two arms suggests that upfront BR is not mandatory in aNSCLC with aBM but this trial failed to show that deferring BR for aBM is superior in terms of PFS from upfront BR.
Identifiants
pubmed: 33948123
doi: 10.1177/17588359211006983
pii: 10.1177_17588359211006983
pmc: PMC8053829
doi:
Banques de données
ClinicalTrials.gov
['NCT02162537']
Types de publication
Journal Article
Langues
eng
Pagination
17588359211006983Informations de copyright
© The Author(s), 2021.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
JAMA Oncol. 2017 Jun 1;3(6):827-831
pubmed: 27892978
J Neurooncol. 2013 May;112(3):461-6
pubmed: 23420398
Cancer. 2007 Sep 1;110(5):1077-82
pubmed: 17614294
Neuro Oncol. 2012 Sep;14(9):1171-7
pubmed: 22898372
Lung Cancer. 2010 May;68(2):258-63
pubmed: 19592127
Lung Cancer. 2010 May;68(2):264-8
pubmed: 19632738
Neuro Oncol. 2012 Apr;14(4):491-5
pubmed: 22362813
Cancer. 2008 Jul 1;113(1):143-9
pubmed: 18459180
Cancer Treat Rev. 2016 Apr;45:139-62
pubmed: 27019457
Lancet Oncol. 2009 Nov;10(11):1037-44
pubmed: 19801201
Clin Cancer Res. 2010 Jan 1;16(1):269-78
pubmed: 20028762
Clin Cancer Res. 2015 Apr 15;21(8):1896-903
pubmed: 25614446
Front Oncol. 2012 Jul 19;2:73
pubmed: 22833841
Cancer Treat Rev. 2014 Jul;40(6):716-22
pubmed: 24759599
Cancer. 2007 Jan 15;109(2):274-81
pubmed: 17154161
Ann Oncol. 2001 Jan;12(1):59-67
pubmed: 11249050
PLoS One. 2020 Apr 16;15(4):e0231546
pubmed: 32298306
J Clin Oncol. 2009 Nov 1;27(31):5255-61
pubmed: 19738122
Curr Cancer Drug Targets. 2012 Mar;12(3):247-59
pubmed: 22229251
Am J Roentgenol Radium Ther Nucl Med. 1971 Feb;111(2):334-6
pubmed: 5541678
Lancet Oncol. 2020 May;21(5):655-663
pubmed: 32251621
Cochrane Database Syst Rev. 2012 Apr 18;(4):CD003869
pubmed: 22513917
Ann Oncol. 2015 Apr;26(4):762-768
pubmed: 25538174
Ann Oncol. 2011 Nov;22(11):2466-2470
pubmed: 21321089
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Lancet. 2016 Oct 22;388(10055):2004-2014
pubmed: 27604504
Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):710-7
pubmed: 25752382
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
J Clin Oncol. 2004 Jul 15;22(14):2865-72
pubmed: 15254054
Eur J Cancer. 2018 Apr;93:37-46
pubmed: 29477100